HOPA Annual Conference 2019

Session descriptions and speaker information for sessions on Wednesday, April 3, at HOPA's Annual Conference.



Preconference Session (0.4 CEU) (extra-fee event)

UAN 0465-0000-19-041-L04-P blue K

Residency Program Director and Preceptor Development (001)

Precepting students and residents is a standard component of oncology pharmacy practice. Equipping preceptors with tools for giving effective feedback, fostering layered learning, precepting in a nontraditional or ambulatory setting, and developing leadership skills and professionalism will be beneficial to current and prospective preceptors. In addition, with the recent changes in the standards for oncology residencies, it is important to understand the current requirements and to discuss details and implementation challenges. This session will review accreditation standards for the design and conduct of a residency program, including requirements related to program purpose, competency areas, goals and objectives, program structure, learning experiences, orientation, use of preceptor roles, evaluation, resident development plans, and continuous residency program improvement. This preconference session will include a combination of didactic learning and facilitated small-group discussion.

Andrea Iannucci, PharmD BCOP
Andrea Landgraf Oholendt, PharmD BCOP
Jane Pruemer, PharmD BCOP FASHP
Nelly Adel, PharmD BCOP BCPS


Preconference Session (0.4 CEU) (extra-fee event)

UAN 0465-0000-19-042-L04-P blue K

Palliative Care Toolbox for Oncology Pharmacists (002)

Developed and presented by the Society of Pain and Palliative Care Pharmacists (SPPCP) Accredited by the Hematology/Oncology Pharmacy Association (HOPA)

Pharmacists in the oncology setting are poised to provide pharmaceutical care to improve patients’ quality of life through symptom management and through detection and prevention of medication-related adverse effects that contribute to an oncology patient’s symptom burden. Palliative care teams rely on pharmacists’ expertise to optimize medication therapy, and oncology pharmacists have an opportunity to develop palliative care skills with the oncology and palliative care teams at their institutions to help optimize patient care. The presenters will review core palliative care medication management skills and advanced therapeutics used for complex symptom management. Add these tools to your toolbox through a fast-paced discussion of these minitopics: opioid conversions; complex pain management and the role of methadone, ketamine, lidocaine, and dexmedetomidine; screening for risk of opioid misuse and management of patients with opioid use disorder; palliative sedation; palliative extubation and withdrawal of respiratory support; refractory GI symptoms; delirium; and communication skills for the oncology pharmacist wading into palliative care.

Benjamin Kematick, PharmD
Victor Phantumvanit, PharmD BCOP BCPS
Bridget Scullion, PharmD BCOP
Iman Suliman, PharmD

12:30–1:30 pm

General Session (0.1 CEU)

UAN 0465-0000-19-010-L04-P Included in virtual meeting blue K

Promoting Resilience and Preventing Burnout: Strategies for Having a Long, Fulfilling Career (101)

Given the patient population that they work with, oncology pharmacists need to better understand and cope with feelings of burnout. This session will address burnout in the healthcare setting: how to identify it, strategies for preventing it, and coping mechanisms for when it occurs.

Justin Baker, MD FAAHPM

12:30–1:30 pm

BCOP Session  (0.1 CEU)

UAN 0465-0000-19-032-L04-P Included in virtual meeting red A

Updates in the Management of Prostate Cancer (BC1)

Over the past year, several advances in screening recommendations and treatment of prostate cancer have occurred. This session will provide an update to guideline recommendations for prostate cancer screening, highlighting important differences. Data on the two new available therapies for the treatment of nonmetastatic castration-resistant prostate cancer will be shared as well as guidance that can be used to select the most appropriate treatment for metastatic hormone-sensitive prostate cancer. The session will close with a discussion of genomics in prostate cancer, including what the common mutations are, when to test for mutations, and how to treat if mutations are present.

Lisa Holle, PharmD BCOP FHOPA

12:30–1:30 pm

General Session (0.1 CEU)

UAN 0465-0000-19-011-L04-P Included in virtual meeting blue K

Investigational Medications (102)

The development of new anticancer agents with novel mechanisms of action is one of the most rapidly changing aspects of cancer research. Several key areas in drug development are affecting the care of oncology patients. These drug classes include small molecules, biologic agents, and immuno-oncology drugs. Rapid advances have been made in CAR-T cell therapy construction and adverse effect management. Likewise, the FDA continues to weigh in on clinical trials by endorsing novel end points and the use of natural history models to hasten the evaluation of medication therapies. In this ever-changing research and drug development landscape, it is imperative that the clinical oncology pharmacist be able to interpret results of early- and late-phase clinical trials and that the pharmacy practice leader be able to ascertain the appropriateness of adding newly approved oncology medications to the formulary. Practice leaders are also challenged with ensuring that their institutions are compliant with USP <800> for investigational agents. The presenter will review emerging clinical and practice information for investigational medications that are likely to be available for general use in the near future.

Barry Goldspiel, PharmD BCOP BCPS FHOPA

3–4:15 pm

General Session (0.125 CEU)

UAN 0465-0000-19-043-L04-P Included in Virtual Meetingblue K

The Oncology Pharmacist’s Blind Spot: A Practical Roadmap to Patient Outreach (103)

This session will help make HOPA members aware of the resources and opportunities available to patients, pharmacists, nonpharmacist providers, and the HOPA organization from partnering patient advocacy organizations. The session has three parts: (1) introduction and educational component, (2) a patient experience, and (3) a panel discussion. The current collaboration between HOPA and patient advocacy organizations will be described. The panel will include a patient, representatives from one or two of the partner organizations, and the chair and vice-chair of HOPA’s Patient Outreach Committee. The need to increase oncology pharmacists’ emotional intelligence, provide patient support training, and raise outreach awareness for our membership has not yet been met, and despite our best efforts, many cancer patients and caregivers continue to have their needs go unaddressed. Additionally, being familiar with and managing cancer information materials can be overwhelming for both the healthcare professional and the patient. This session will influence practice by pharmacists in all settings, provide them with new tools and resources, and stimulate ideas for professional growth opportunities in their local community.

Jill Rhodes, PharmD BCOP
Kellie Jones Weddle, PharmD BCOP FCCP FHOPA

3–4:15 pm

BCOP Session  (0.125 CEU)

UAN 0465-0000-19-033-L04-P Included in virtual meetingred A

Young Adults and Adolescents: Current and Future Challenges (BC2)

This session will focus on how the treatment of cancer may affect the long-term health of patients from adolescents through the elderly. The presenters will review strategies for reducing the impact of late and specific effects of treatment on these patients. Topics will include fertility preservation, strategies to manage hormone-related symptoms, and opportunities to reduce long-term morbidity related to chemotherapy. This session is directed toward those who care for adolescent, young adult, and adult patients and to providers who have an active role in the care of long-term survivors.

Joseph Sciasci, PharmD BCOP BCPS
Mary Mably, RPh BCOP

4:30–5:15 pm

General Session (0.075 CEU)

UAN 0465-0000-19-012-L04-P Included in Virtual Meeting blue K

Updates in Renal Cell Carcinoma (104)

Previous landmark trials helped outline optimal second-line and subsequent therapy for patients with renal cell carcinoma (RCC). Recently, new clinical trials have reported data that shed light on a new preferred front-line tyrosine kinase inhibitor and the use of combination immunotherapy. Prognostic criteria are also used earlier to select treatment options. Information on predictive biomarkers and head-to-head comparison of targeted therapy versus immunotherapy is still lacking, requiring the oncology pharmacist to use the available evidence and patient-specific factors in clinical decision making. Review of clinical trials and important pharmacy pearls and future directions in the paradigm of RCC management will help the oncology pharmacist tailor treatment recommendations for patients.

Kinjal Parikh, PharmD BCOP

4:30–5:15 pm

Flipped Classroom (0.075 CEU) Additional 0.5 CE prework available

UAN 0465-0000-19-013-L04-P  Included in virtual meetingblue K

Key Updates in Internal Medicine: What the Oncology Pharmacist Needs to Know (105)

Cancer patients often present with comorbidities such as heart failure, diabetes, and hypertension, creating a need for oncology pharmacists to be familiar with the appropriate guidelines and standards of care for these areas. The demands of a continually evolving specialty area require practicing oncology pharmacists to devote the majority of their professional time to the oncology sector. Consequently, it can be difficult for them to keep abreast of internal medicine updates. This session will review the latest guidelines and 2018 guideline updates in the areas of heart failure, diabetes, and hypertension, enabling the oncology pharmacist to remain fluent in internal medicine.

Tara Lech, PharmD BCPS